Finance

Beta
Lists
42C:SGX
IX Biopharma Ltd
SGD 0.36
+2.90%
(+0.0100) 1D
Jun 5, 5:04:45 PM GMT+8  ·   SGD
All symbols
SymbolPriceChange% Change
Generating top insights for 42C...
Open
SGD 0.35
High
SGD 0.36
Low
SGD 0.34
Mkt. cap
369.88M
Avg. vol.
14.71M
Volume
7.86M
52-wk high
SGD 0.46
52-wk low
SGD 0.02
Shares outstanding
1.06B
No. of employees
35
Open
SGD 0.35
High
SGD 0.36
Low
SGD 0.34
Mkt. cap
369.88M
Avg. vol.
14.71M
Volume
7.86M
52-wk high
SGD 0.46
52-wk low
SGD 0.02
Shares outstanding
1.06B
No. of employees
35
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to 42C in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for 42C in the last 3 months.
Highest
Current SGD 0.36
SGD 1.00 (+181.69%)
Average
SGD 1.00 (+181.69%)
Lowest
SGD 1.00 (+181.69%)
News stories
From sources across the web
About IX Biopharma Ltd
CEOEddy Lee
Employees35
Founded2004
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in SGD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SGD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.03M
1.59M
1.59M
1.59M
Cost of goods sold
1.42M
1.18M
1.18M
983.00K
Cost of revenue
1.42M
1.18M
1.18M
983.00K
Research and development expenses
406.50K
203.00K
203.00K
769.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.54M
1.72M
1.72M
1.71M
Operating expense
1.95M
1.94M
1.94M
2.48M
Total operating expenses
3.37M
3.12M
3.12M
3.46M
Operating income
-1.34M
-1.53M
-1.53M
-1.87M
Other non operating income
-113.00K
66.00K
66.00K
1.12M
EBT including unusual items
-1.94M
-1.03M
-1.03M
-915.00K
EBT excluding unusual items
-1.94M
-1.03M
-1.03M
-915.00K
Income tax expense
500.00
500.00
500.00
1.00K
Effective tax rate
-0.03%
-0.05%
-0.05%
-0.11%
Other operating expenses
-
-
-
-
Net income
-1.95M
-1.03M
-1.03M
-916.00K
Net profit margin
-95.98%
-64.76%
-64.76%
-57.65%
Earnings per share
-
-
-
-
Interest and investment income
9.00K
-
-
-
Interest expense
-96.50K
-201.50K
-201.50K
-164.00K
Net interest expenses
-87.50K
-201.50K
-201.50K
-164.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.24M
-1.44M
-1.44M
-1.52M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more